Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

9 Months Ended

Mar. 31, 2021

Schedule of Stockholders Equity [Table Text Block]

	Bio-Techne Shareholders
													Accumulated
							Additional						Other
	Common Stock						Paid-in			Retained			Comprehensive			Noncontrolling
	Shares			Amount			Capital			Earnings			Income(Loss)			Interest			Total
Balances at June 30, 2020		38,453		$	385		$	420,536		$	1,057,470		$	(97,199	)	$	-		$	1,381,192
Cumulative effect adjustments due to adoption of new accounting standards											(276	)								(276	)
Net earnings											33,395									33,395
Other comprehensive income														14,057						14,057
Common stock issued for exercise of options		117			1			13,727												13,728
Common stock issued for restricted stock awards		25			0			(0	)		(4,890	)								(4,890	)
Cash dividends											(12,336	)								(12,336	)
Stock-based compensation expense								12,667												12,667
Common stock issued to employee stock purchase plan		6			0			1,463												1,463
Employee stock purchase plan expense								286												286
Balances at September 30, 2020		38,601		$	386		$	448,679		$	1,073,362		$	(83,142	)	$	-		$	1,439,285
Non-controlling interest in Eminence																	8,985			8,985
Net earnings											46,274						(130	)		46,144
Other comprehensive income														18,904			83			18,987
Common stock issued for exercise of options		161			2			16,748			(2,482	)								14,268
Common stock issued for restricted stock awards		3			0			(0	)		0									0
Cash dividends											(12,392	)								(12,392	)
Stock-based compensation expense								15,471												15,471
Employee stock purchase plan expense								106												106
Balances at December 31, 2020		38,765		$	388		$	481,004		$	1,104,762		$	(64,238	)	$	8,938		$	1,530,854
Net earnings											45,782						(380	)		45,402
Other comprehensive income														215			(69	)		146
Share repurchases		(120	)		(1	)					(43,177	)								(43,178	)
Common stock issued for exercise of options		195			2			21,324			(4,332	)								16,994
Common stock issued for restricted stock awards		10			0			(0	)		(1,801	)								(1,801	)
Cash dividends											(12,446	)								(12,446	)
Stock-based compensation expense								10,232												10,232
Common Stock issued to employee stock purchase plan		4			0			1,328												1,328
Employee stock purchase plan expense								411												411
Balances at March 31, 2021		38,854		$	389		$	514,299		$	1,088,788		$	(64,023	)	$	8,489		$	1,547,942

												Accumulated
						Additional						Other
	Common Stock					Paid-in			Retained			Comprehensive
	Shares			Amount		Capital			Earnings			Income(Loss)			Total
Balances at June 30, 2019		37,934		$	379	$	316,797		$	931,934		$	(83,521	)	$	1,165,589
Cumulative effect adjustments due to adoption of new accounting standards and other										(879	)					(879	)
Net earnings										14,398						14,398
Other comprehensive loss													(8,106	)		(8,106	)
Common stock issued for exercise of options		94			1		7,854									7,855
Common stock issued for restricted stock awards		50			0		(0	)		(1,926	)					(1,926	)
Cash dividends										(12,169	)					(12,169	)
Stock-based compensation expense							8,267									8,267
Common stock issued to employee stock purchase plan		6			0		1,096									1,096
Employee stock purchase plan expense							99									99
Balances at September 30, 2019		38,084		$	381	$	334,112		$	931,358		$	(91,627	)	$	1,174,224
Net earnings										119,622						119,622
Other comprehensive loss													13,275			13,275
Common stock issued for exercise of options		195			2		18,293									18,295
Common stock issued for restricted stock awards		4			0		(0	)								0
Cash dividends										(12,197	)					(12,197	)
Stock-based compensation expense							10,017									10,017
Common stock issued to employee stock purchase plan
Employee stock purchase plan expense							112									112
Balances at December 31, 2019		38,283		$	383	$	362,534		$	1,038,783		$	(78,352	)	$	1,323,348
Net earnings										36,432						36,432
Other comprehensive income (loss)													(25,105	)		(25,105	)
Share Repurchases		(279	)		(3)		0			(50,109	)					(50,112	)
Common stock issued for exercise of options		100			1		10,026									10,027
Common stock issued for restricted stock awards		1			0		(0	)		(114	)					(114	)
Cash dividends										(12,279	)					(12,279	)
Stock-based compensation expense							7,745									7,745
Common stock issued to employee stock purchase plan		8			0		1,216									1,216
Employee stock purchase plan expense							110									110
Balances at March 31, 2020		38,112		$	381	$	381,632		$	1,012,713		$	(103,458	)	$	1,291,268

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Unrealized Gains (Losses) on Derivative Instruments			Foreign Currency Translation Adjustments			Total
Balance as of June 30, 2020 attributable to Bio-Techne	$	(13,253	)	$	(83,946	)	$	(97,199	)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne		(13	)		27,686			27,673
Reclassification from loss on derivatives to earnings, net of taxes, attributable to Bio-Techne⁽¹⁾		5,503			-			5,503
Balance as of March 31, 2021 attributable to Bio-Techne⁽³⁾	$	(7,763	)	$	(56,260	)	$	(64,023	)

	Unrealized Gains (Losses) on Derivative Instruments			Foreign Currency Translation Adjustments			Total
Balance as of June 30, 2019 attributable to Bio-Techne	$	(9,537	)	$	(73,983	)	$	(83,521	)
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne		(6,413	)		(15,138	)		(21,551	)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne⁽²⁾		1,614			-			1,614
Balance as of March 31, 2020 attributable to Bio-Techne⁽³⁾	$	(14,336	)	$	(89,121	)	$	(103,458	)